Kestra Medical Technologies Files 8-K for Material Agreement

Ticker: KMTS · Form: 8-K · Filed: Dec 4, 2025 · CIK: 1877184

Kestra Medical Technologies, LTD. 8-K Filing Summary
FieldDetail
CompanyKestra Medical Technologies, LTD. (KMTS)
Form Type8-K
Filed DateDec 4, 2025
Risk Levelmedium
Pages3
Reading Time4 min
Key Dollar Amounts$1.00, $23.00, $148.4 m
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, 8-k

TL;DR

KESTRA MEDICAL TECHNOLOGIES (KMTI) filed an 8-K on 12/4/25 for a material definitive agreement dated 12/2/25.

AI Summary

Kestra Medical Technologies, Ltd. filed an 8-K on December 4, 2025, reporting a material definitive agreement entered into on December 2, 2025. The filing also includes financial statements and exhibits. The company's principal executive offices are located in Kirkland, Washington.

Why It Matters

This 8-K filing indicates Kestra Medical Technologies has entered into a significant agreement, which could impact its business operations and future financial performance.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood by the market.

Key Numbers

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Kestra Medical Technologies?

The filing does not specify the nature of the material definitive agreement, only that one was entered into on December 2, 2025.

When was this 8-K report filed?

The 8-K report was filed on December 4, 2025.

Where are Kestra Medical Technologies' principal executive offices located?

The principal executive offices are located at 3933 Lake Washington Blvd NE, Suite 200, Kirkland, Washington 98033.

What is the company's SIC code?

The Standard Industrial Classification (SIC) code is 3841, for SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.

What is the company's fiscal year end?

The company's fiscal year ends on April 30.

Filing Stats: 969 words · 4 min read · ~3 pages · Grade level 12.6 · Accepted 2025-12-04 16:30:20

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated December 2, 2025 by and among Kestra Medical Technologies, Ltd., BofA Securities, Inc., Piper Sandler & Co., J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 4, 2025 Kestra Medical Technologies, Ltd. By: /S/ Brian Webster Name: Brian Webster Title: President, Chief Executive Officer and Director

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing